profit from every $100 of sales.
$0$100
DocGo
$0.23-2.98% today
-79.4% in 1 year
1-year low $0.211-year high $1.09
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What DocGo sold, what it kept, and what it did with the cash.
Sales went from $441 million in 2022 to $322 million in 2025, with -$182 million of profit last year.
SalesProfit
DocGo handed back 40% of the cash it generated last year.
Buybacks $11M
Free cash flow 2025$27M
Bought back its own shares$11M
Paid as dividends–
Cash vs. debt$51M vs. $29M
DocGo vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| DocGo | No profit yet | ||
 HCA Healthcare | 15.4× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.7× · Fair price | ||
 IHH Healthcare Berhad | 33.3× · Expensive | ||
 Rede D'Or São Luiz | 15.8× · Fair price |
AI analysis
An AI analyst reads DocGo's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 441 | 624 | 617 | 322 | |
| 155 | 195 | 214 | 99 | |
| 22 | 15 | 29 | -89 | |
| 32 | 31 | 45 | -73 | |
| 35 | 7 | 20 | -182 | |
| 0.34 | 0.06 | 0.18 | -1.84 | |
| 35.1% | 31.3% | 34.6% | 30.7% | |
| 5.0% | 2.4% | 4.7% | -27.7% | |
| 7.9% | 1.1% | 3.2% | -56.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 393 | 490 | 456 | 217 |
| Cash | 157 | 59 | 89 | 51 |
| Total debt | 20 | 46 | 57 | 29 |
| Total liabilities | 114 | 185 | 140 | 91 |
| 273 | 301 | 321 | 144 | |
| 103 | 106 | 109 | 99 | |
| 5.9% | 3.4% | 6.0% | -40.7% | |
| 12.7% | 2.3% | 6.2% | -126.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 29 | -64 | 70 | 34 | |
| 5 | 10 | 6 | 7 | |
| 23 | -74 | 65 | 27 | |
| Dividends paid | – | – | – | – |
| 4 | 0 | 14 | 11 | |
| 8 | 21 | 14 | 17 |
Valuation
- –
- –
- –
- 0.4×
- 0.1×
- 0.8×
- –
- 121.3%
- -818.9%
- 0.0%
Profitability
- 30.7%
- -27.7%
- -56.6%
- -16.2%
- -41.7%
- -6.5%
- -44.6%
- -7.1%
- -14.2%
- 4.9%
Growth
- −9.9%
- –
- −58.1%
- –
- −1.3%
Financial health
- -0.3×
- 0.20
- 4.9%
- 187.6×
- 2.26
- 1.79
- 0.36
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 952
Bottom 10%of 883
Bottom 7%of 870
What analysts expect
- Average price target
- $1.50
- Range
- $1.50 – $1.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.12 | -0.02 | −500.0% |
| Mar 16, 2026 | -0.53 | -0.10 | −430.0% |
| Nov 10, 2025 | -0.11 | -0.15 | +26.2% |
| Aug 7, 2025 | -0.11 | -0.10 | −10.0% |
| May 8, 2025 | -0.09 | -0.03 | −184.2% |
| Feb 27, 2025 | 0.04 | 0.05 | −20.0% |
| Nov 7, 2024 | 0.05 | 0.05 | +0.0% |
| Aug 7, 2024 | 0.07 | 0.08 | −12.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
71Pass
Philip Fisher
33No pass
Peter Lynch
27No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
21No pass
Questions about DocGo
Is DocGo a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the DocGo AI analysis
What does DocGo do?
DocGo Inc. operates as a mobile healthcare services company in the United States and the United Kingdom. It operates through Mobile Health Services and Transportation Services segments. It is in Medical Care Facilities.
Does DocGo pay a dividend?
No. DocGo does not pay a dividend at the moment; in 2025 it returned $10.8 million to shareholders by buying back its own shares.
Is DocGo stock halal?
No. DocGo does not pass our halal screen: its debt is 131% of its market value, at or above the 33% limit. How we check
How has DocGo stock done over the past year?
Down 79.4% over the past twelve months, to $0.23. It traded between $0.21 and $1.09 and is 79.4% below its high.
Who are DocGo's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with DocGo's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.